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B
ased on the results of the U.K. Pro-
spective Diabetes Study (UKPDS),
“. . . treatment of type 2 diabetes
[should] include aggressive efforts to
lowerbloodglucoselevelsasclosetonor-
mal as possible.... ”This was the recom-
mendation the American Diabetes
Association promulgated based on the
resultsoftheUKPDSwhenpublished(1).
The suggestion was soon adopted by ofﬁ-
cial guidelines in every region of the
world(2).Theyaregenerallyconsistentin
recommending an A1C goal of 7.0%.
However, the results of the UKPDS re-
mained inconclusive with respect to car-
diovascular (CV) complications because
of a risk reduction that was only close to
statistical signiﬁcance (16%, P 
0.052). In support of the UKPDS results,
however, a recent meta-analysis of ran-
domized trials in type 2 diabetes (3) cal-
culated a 19% reduction in the incidence
of any type of macrovascular event asso-
ciated with improved long-term glycemic
control. Moreover, a strong association
between glycemic control and micro- and
macrovascular disease has been high-
lighted in type 1 diabetic patients (4,5).
Nevertheless, these results have been
challenged by recent large-scale interven-
tion trials. The Action to Control Cardio-
vascular Risk in Diabetes (ACCORD) trial
randomized 10,000 subjects with type
2 diabetes and vascular disease, or multi-
ple CV risk factors, to an intensive treat-
ment program targeting normal blood
glucose values and A1C 6%, or a stan-
dard treatment program aiming at A1C
between 7 and 7.9%. The intensive blood
glucosearmwasprematurelystoppedbe-
cause of excess mortality (hazard ratio
[HR] 1.22, 95% CI 1.01–1.46; P  0.04)
and lack of signiﬁcant reduction of pri-
mary outcome, i.e., a composite of nonfa-
tal myocardial infarction, nonfatal stroke,
or death from CV causes (HR 0.90, 0.78–
1.04;P0.16)(6).Afteramedian5-year
follow-up, the Action in Diabetes and
VascularDisease:PreteraxandDiamicron
MR Controlled Evaluation (ADVANCE),
the largest-ever study of strategy of inten-
sive glucose control, involving 11,140
high-risk type 2 diabetic patients, pro-
vided no evidence of major CV event re-
duction (HR 0.94, 0.84–1.06; P  0.32)
when A1C was lowered to 6.5% (7). Sim-
ilarresultshavebeenachievedbytheVet-
eransAdministrationDiabetesTrial(8).It
is noteworthy that all three trials com-
prised patients with diabetes of long-
standing duration, and in two of the
studies, subjects with previous CV events
were included, leaving unaltered (or at
least unsettled) the importance of achiev-
ing and maintaining good glycemic con-
trol from the time of diabetes diagnosis.
This view is supported by the results of
the 10-year follow-up of the UKPDS (9).
Despite early loss of glycemic differences,
signiﬁcantreductionintheriskformicro-
vascular complications, myocardial in-
farction, and all-cause mortality was
observed in patients originally in the in-
tensive treatment group.
The number of newly diagnosed type
2 diabetic patients achieving, and even
more importantly, maintaining glycemic
targetislimited.Nospeciﬁcdataareavail-
able,butintheUKPDS,whichcomprised
only newly diagnosed type 2 diabetic pa-
tients with no previous CV events, aver-
age A1C was 7%. This threshold value,
however, was not maintained for 4
years (1), and more recent data indicated
that 50% of this patient population is at
target (10). Therefore, effective treatment
for type 2 diabetes would require an early
andeffectiveintervention,thoughﬂexible
enough to ensure longstanding metabolic
control. To set new paradigms of treat-
ment, strategies should be elaborated that
identify and overcome current limita-
tions.Manyhurdlesmayhamperthepos-
sibility of a greater number of patients
achieving target, and a tentative list of
such factors is given in Table 1 and dis-
cussed in this article.
INEFFECTIVE DIET AND
EXERCISE INITIATIVES— Diet
and exercise remain the cornerstone of
treatment of type 2 diabetes, as recently
conﬁrmed by the European Association
for the Study of Diabetes/American Dia-
betes Association treatment algorithm
(11), but for lifestyle modiﬁcation to be
effective,itrequireslong-termadherence.
Look AHEAD (Action for Health in Dia-
betes) (12) is the ﬁrst large clinical trial
investigating long-term health impact of
intensive lifestyle intervention in 5,145
overweight or obese adults with type 2
diabetes. Follow-up is ongoing and is
planned to continue for 11.5 years to as-
sess whether CV morbidity and mortality
can be reduced by long-term weight re-
duction achieved by diet, physical activ-
ity, and behavior modiﬁcation. At 1 year,
body weight decreased by 8.6% and the
percentageofparticipantswithA1C7%
increasedfrom46to73%withadoubling
(from 10 to 23.6%) of those achieving
guideline goals for glycemic, blood pres-
sure, and lipid control (12). Whether
theseinitialfavorableeffectswillbemain-
tained over time and whether they will be
transformed into a CV beneﬁt will be ver-
iﬁed in the ensuing follow-up.
More apparent in the interim is the
impact of lifestyle modiﬁcations for pre-
ventionoftype2diabetes,asindicatedby
the 58% reduction in the conversion rate
to overt diabetes in the high-risk popula-
tions of the Diabetes Prevention Program
(13) and Diabetes Prevention Study (14).
Nonetheless, despite these striking re-
sults,implementationofsimilarprograms
in the general population remains prob-
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pensive enough to require dedicated
political decisions.
LIMITED PHARMACOLOGIC
ARMAMENTARIUM— The ideal
antidiabetic agent should normalize
plasmaglucoseproﬁles,minimizesideef-
fects, and prevent development of micro-
and macrovascular complications. Obvi-
ously no such agent is available, nor is
it likely to be available in the near or
medium-term future. Table 2 clearly
shows there is no shortage of antidiabetic
drugs,withevenmoretocome(15).Each
of these agents has pros and cons, but
even more importantly, none of them is
likely to ensure sustained good glycemic
control over time. Although the UKPDS
experience is limited to traditional antidi-
abetic agents, it has disseminated a valu-
able lesson. Regardless of the agent
initially prescribed to the patient, ulti-
mately, glycemic control trespassed on
the target threshold. The question may be
rephrasedastowhetherthereistreatment
that provides more durable efﬁcacy. This
issue has been recently dealt with in A
Diabetes Outcome Progression Trial
(ADOPT). In this study, the cumulative
incidence of monotherapy failure at 5
years was highest with glyburide (34%;
P  0.001), intermediate with metformin
(21%), and lowest with rosiglitazone
(15%, P  0.001) (16). The longer dura-
bilityofrosiglitazonehasbeeninterpreted
on the basis of simultaneous improve-
mentofthetwomainpathogeneticmech-
anisms of type 2 diabetes, i.e., insulin
resistance and -cell function. Loss of
-cell function is the main reason for de-
teriorationofglucosetoleranceandglyce-
mic control (17), and glitazones have
been claimed to preserve -cell function
(18). From this perspective, vast interest
hasgeneratedtheavailabilityofglucagon-
like peptide (GLP)-1 analogs and dipep-
tidyl peptidase-4 inhibitors based on
preclinical studies suggesting mainte-
nance of -cell function and mass with
these drugs (19). These intriguing but
preliminary ﬁndings require clinical con-
ﬁrmation, so that for the moment, it
would be unwise to anticipate the
“golden” treatment; rather, it would be
preferable to learn how to better use the
available pharmacologic tools.
CONSERVATIVE
MANAGEMENT— The “stepwise
approach”’ is usually adopted to manage
glycemic control in type 2 diabetes. On
diagnosis, lifestyle modiﬁcation is initi-
ated, followed by treatment with a single
oral antidiabetic agent, which is often up-
titrated to maximal recommended doses
before combination therapy is intro-
duced. However, this conservative ap-
proach has a number of drawbacks. On
the contrary, a proactive approach and
therapy tailored to the individual by me-
thodical selection among available agents
can optimize patient care (20).
Several clinical trials have demon-
strated the effectiveness of diet and exer-
cise in preventing diabetes and reducing
diseaseprogression(13,14),but,asafore-
mentioned, such regimens are difﬁcult to
implement and maintain, and glycemic
control is rarely achieved. Hence, in con-
junction with lifestyle intervention, phar-
macologic approaches become the key
component of diabetes management to
the point that the recent American Diabe-
tes Association/European Association for
the Study of Diabetes consensus sug-
gested nutritional therapy should be ini-
tiated together with metformin (11). The
latter is almost unanimously recognized
as the drug of choice, but failure is ex-
pected to occur. In the UKPDS, after
9-year monotherapy, cumulative inci-
denceoffailurewas87%inobesepatients
randomized to metformin (21). In
ADOPT, the 5-year cumulative incidence
ofmetforminfailurewas21%(16),andin
two large retrospective analyses (22,23),
the rate of metformin secondary failure
was 35.5 and 38% at 4 and 5.7 years,
respectively. Although different deﬁni-
tions for failure were used in these stud-
ies, all suggested that unacceptable
therapeutic inertia occurs in clinical prac-
tice. Analysis of the 1994–2002 Kaiser
Permanente Northwest database revealed
that the average time between achieving
A1C action point of 8% and switching to,
or adding a second oral antidiabetic agent
for patients on metformin, or sulfonyl-
urea monotherapy, was 14.5 or 20.5
months, respectively (24). The authors of
this analysis concluded that, “Clinicians
should change glucose-lowering treat-
ments in type 2 diabetes much sooner or
use treatments that are less likely to fail”
(24).Thisviewhasbeenreinforcedbythe
Global Partnership of Effective Diabetes
Management (20) and by the American
Association of Clinical Endocrinologists
(25). Taking the same approach is the
more recent American Diabetes Associa-
tion/European Association for the Study
of Diabetes consensus statement advocat-
ing individualized therapeutic choices to
be considered as soon as A1C overcomes
a 7.0% threshold (11), supporting more
intensive and earlier use of combination
therapy and introduction of insulin ther-
apy if glycemic control is not achieved.
Several studies have shown how early use
of submaximal combination doses of
agents can improve glycemic control
without signiﬁcantly increasing side ef-
fects (26,27). The use of multiple drugs
should be considered not simply on the
basis of greater efﬁcacy, but also in terms
of a rational therapeutic approach of the
multiple pathogenetic mechanisms un-
derlying hyperglycemia and its progres-
sion. In particular, the primary role of
progressive loss of -cell function should
Table 1—Barriers in achieving and main-
taining glycemic control in type 2 diabetic
patients
● Ineffective diet/exercise initiatives
● Lack of efﬁcacy of pharmacological agents
● Conservative management
● Adverse events
● Poor compliance
● Underlying pathophysiology
● Suboptimal health care systems
Table 2—Available antidiabetic agents for
treatment of type 2 diabetes
Sulfonylureas
First generation
Second generation
Third generation
Modiﬁed release
Glinides
Nonsulfonylureic
Amino acid derivatives
Biguanides
Metformin
Thiazolidinediones
Rosiglitazone
Pioglitazone
Fixed-dose oral hypoglycemic agents
combinations
-Glucosidase inhibitors
Acarbose
Voglibose
Insulin
Regular
Long-acting
Pre-mixed
Insulin analogs
Rapid-acting
Long-acting
Inhaled
GLP-1 analogs
Dipeptidyl peptidase-4 inhibitors
Amylin analog
Type 2 diabetes treatment
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cussed hereunder.
ADVERSE EVENTS— In adopting
a more intensive early intervention, the
possibility of incurring adverse events
may be higher compared with more re-
laxedtreatmentstrategies.Moreover,side
effects of the antihyperglycemic therapy
mayaffectpatientcompliance.Theproﬁle
of a drug is best described by its efﬁcacy-
to-safety ratio, but this ratio may vary as a
functionofthedoseused.Atypicalexam-
ple is provided by metformin (28). A pro-
gressive reduction in A1C is observed by
increasing the dose from 500 up to 2,000
mg/day, with no further improvement in
glycemic control above such dosage. On
the contrary, progressive increase in met-
formin dose is associated with increased
prevalence of patients experiencing gas-
trointestinal distress. As aforementioned,
early combination therapy allows use of a
submaximal dose of hypoglycemic
agents, thus reducing the risk of adverse
events. In the EMPIRE study (26), pa-
tients were randomized to either 2,000
mg/day metformin or the combination of
1,000 mg metformin plus 8 mg/day ros-
iglitazone. Although there was no signiﬁ-
cant difference in A1C after 4 months of
treatment, the number of patients who
discontinued because of gastrointestinal-
related adverse events was signiﬁcantly
lower with combination therapy (all gas-
trointestinal events 3.1 vs. 6.8%; diarrhea
1.6 vs. 4.2%; abdominal pain 1.0 vs.
2.3%). Conversely, incidence of edema
and body weight gain is lower when gli-
tazones are associated with metformin
compared with association with sulfonyl-
ureasandinsulin.TheGLP-1analogsand
dipeptidyl peptidase-4 inhibitors possess
an interesting safety proﬁle associated
with body weight loss or neutrality (18),
but the risk of hypoglycemia, which is
almost nonexistent with monotherapy,
becomes a factor when these agents are
combined with sulfonylureas. Hypogly-
cemia is indeed the main concern in the
context of intensive treatment initiated at
the time of diagnosis of type 2 diabetes.
The incidence of hypoglycemia in these
patientshasbeenrecentlyanalyzedbythe
U.K. Hypoglycemia Study Group (29),
whichshowedthatevenwithearlyinsulin
useinthiscondition,thefrequencyofhy-
poglycemia was generally equivalent to
that observed in patients treated with sul-
fonylureas and considerably lower than
during the ﬁrst 5 years of treatment in
type 1 diabetes. This low rate of hypogly-
cemia in type 2 diabetes may be further
reduced by accurate selection of treat-
ment. Thus, insulin sensitizers are not as-
sociatedwithhypoglycemia,itsincidence
is very low with incretin-based therapy,
and use of both fast- and long-acting in-
sulin analogs have been reported to be
associated with less hypoglycemic events
(30).
POOR COMPLIANCE— Unpre-
dicted adverse events and inadequacy to
cope with them may undermine a pa-
tient’s self-reliability and adherence to
treatment. Lack of compliance is often
perceived with a sense of frustration by
physicians. However, adherence is sub-
jective and difﬁcult to assess in a reliable
manner. Moreover, patients, particularly
those with mild alteration of their meta-
bolic control, may not perceive the seri-
ousness of their disease because of the
absence of symptoms and/or they may
lack conﬁdence in the immediate or fu-
ture beneﬁts of medication. It is impor-
tant for physicians to strive to attain
compliance from their patients. Under-
standing the severity of the disease and
the importance of adherence to pre-
scribed treatment would require more
timedevotedtopatienteducationanded-
ucation reinforcement. In the survey by
Browne at al (31), only 35% of patients
recalledreceivingadviceabouttheirmed-
ication, no more than 10% of patients us-
ing sulfonylureas appreciated the risk of
hypoglycemia,andonly20%ofthosetak-
ing metformin were aware of potential
gastrointestinal side effects. Physicians,
nurses, and pharmacists also had gaps in
their knowledge. Approximately 50% an-
swered questions correctly on the timing,
mechanism of action, and side effects of
oral antidiabetic agents (31). These re-
sultsemphasizetheimportanceofcontin-
ued education and consistency of
information from members of primary
and secondary teams but may also under-
lie medical inertia. As it has been recently
suggested (32), failure to appreciate long-
term beneﬁts of treatment intensiﬁcation
may represent a common mechanism un-
derlying both patient nonadherence and
physician clinical inertia, i.e., “clinical
myopia.”
Polypharmacy may represent an-
other burden to the patient, particularly
inlightofmultifactorialinterventionre-
quired. An increasing number of ﬁxed-
combination tablets of oral agents is
becoming available, and data in the liter-
ature indicate how adherence to therapy
may be more beneﬁcial with these combi-
nations compared with the use of a single
drug tablet (33).
UNDERLYING
PHYSIOPATHOLOGY— Type 2
diabetes is a complex disease where sev-
eral pathogenetic mechanisms coexist, in
particular, insulin resistance and reduced
-cell function (34). Insulin resistance
occurs in 85% of patients and is associ-
ated with impaired insulin-mediated glu-
cose uptake in insulin-dependent tissues
(mainly skeletal muscle) and ineffective
suppression of hepatic glucose produc-
tion. The latter is the main cause for in-
creased fasting plasma glucose levels due
to inappropriate acceleration of glucone-
ogenesis. Insulin resistance is also closely
interlinkedwithnumerousriskfactorsfor
CV disease (35), as well as being an inde-
pendentriskfactorforCVdisease(36).In
individuals predisposed to type 2 diabe-
tes, the early alteration of insulin sensitiv-
ity is already associated with marked
impairment of the -cell. Modest alter-
ation of glucose tolerance, even within
nondiagnostic boundaries, is associated
withmarkedreductionof-cellmassand
function (37). Moreover, it is the progres-
sive loss of -cell mass and function that
sets the pace for transition from normal
glucose tolerance to diabetes. Therefore,
treatments designed to correct pathoge-
netic abnormalities that are already
present in the pre-diabetic condition may
ensureprolongedglycemiccontrol.Based
on this pathophysiological background,
DeFronzo in his Banting Medal Lecture
(38) proposed that triple therapy should
be initiated as early as possible, rather
thanadoptingastepwiseapproachsimply
basedonA1Ctargeting.Accordingtothis
proposal, the effects of which will be
tested in a randomized trial, metformin
will be used to improve insulin action
on the liver, pioglitazone to ameliorate
peripheral insulin action, and GLP-1
analogs (or dipeptidyl peptidase-4
inhibitors) to improve -cell function,
and,possibly,preserve-cellmass.Itisof
interest that the treatment appears to be
safeenoughtobeusedwithconﬁdencein
theearlystageofthedisease,sincenoneof
the three drugs conveys risk for hypogly-
cemia.Moreover,theanti-obesityeffectof
GLP-1 analogs and metformin may pre-
vent glitazone-mediated body weight
gain. Although rationale and fascinating,
this proposal need to be assessed with
proper clinical trials and no implementa-
tion should be considered without pre-
Del Prato, Penno, and Miccoli
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In summary, modern pharmacopeia
facilitates a rational therapeutic approach
aiming at reversal of the alterations that
account for progressive deterioration of
glucose homeostasis, enabling, at least in
theory, maintenance of long-term glyce-
mic control.
SUBOPTIMAL HEALTH CARE
SYSTEM— Effective and sustained
glycemic control in type 2 diabetes is un-
likely to depend only on rational treat-
ment.Education,motivation,prevention,
and development of micro- and macro-
vascular complications, and comorbidi-
ties, are indications for a structured
multidisciplinary approach. Ideally, the
patients should be supported by a multi-
disciplinary team comprising primary
care physicians, diabetologists, diabetes
education nurses, dietitians, pharmacists,
podiatrists, and various other specialists.
Thismultidisciplinaryteamshouldbede-
signed to promptly react to any new edu-
cational, diagnostic, and therapeutic
need. Data are available to support the
notion that with such an approach, glyce-
mic control, hospitalization, and patients’
quality-of-life are all signiﬁcantly im-
proved (39). Continuous education is
also integral to diabetes management,
since it has been repeatedly shown that it
not only improves metabolic control, but
also contributes to more cost-effective in-
tervention (40). While there may be chal-
lenges in applying these approaches due
to economical constraints, the relevance
of involving the patient within the diabe-
tes care team must be acknowledged as
pivotaltoimprovingtheproportionofin-
dividuals achieving good glycemic con-
trol. All components of the diabetes team
should recognize their crucial role in en-
abling and empowering patients to con-
trol their medical condition.
CHANGING THE
PARADIGM— Thegrowingnumber
of individuals with type 2 diabetes, the
still limited therapeutic success, and the
burden of micro- and macrovascular
complications necessitate a change in
treatment of diabetes. Such change can
only occur by overcoming the multiple
limitations hampering our ability to en-
sure adequate longstanding glycemic
control to as many patients as possible. In
previous sections, we tried to outline
some of these limitations. Many others
may be added, but our list may sufﬁce
deliberation.
Obesity is the most common pheno-
typictraitoftype2diabetesanditdirectly
affects the possibility of achieving sus-
tained glycemic control. Unfortunately,
effective anti-obesity drugs are still lack-
ing, particularly after the use of endocan-
nabinoid receptor antagonists has been
halted (41). An even more salient point is
that obesity is the main driving force for
the current epidemic of type 2 diabetes;
thus, ﬁghting obesity represents a major
taskintheattempttopreventthisdisease.
Unfortunately, this tactic is unlikely to be
solved at the individual level. Rather, as
outlined by Simpson et al. (42), a more
comprehensive approach not limited to
high-risk individuals should be adopted
by implementing strategies of lifestyle
modiﬁcation directed at the community,
addressing young generations by intro-
ducingformalandstructurededucational
programs into the school curricula, and
by exposing youngsters to the disaster
and mayhem of states of ill health. All this
requires societal and political decisions,
such as treating metabolic poisoning, i.e.,
high caloric fat content in food with the
same tax penalty approach used for other
health-menacing factors, namely ciga-
rettes, alcohol, and carbon emission.
Diabetes is diagnosed as soon as fast-
ing plasma glucose exceeds 125 mg/dl.
Merely crossing that line does not mean
we are facing a “mild diabetic condition.”
There is no “mild diabetes”; it is diabetes
with the full array of risks for developing
complications that are deﬁnitely a threat
to the quality of life and life expectancy of
patients. Therefore, prompt restoration
and maintenance of glycemic control as
close as, and for as long as possible, to
normal levels, is mandatory.
To achieve this goal, advantages and
disadvantages of available therapeutic
tools should be mastered by the diabe-
tologist. This is necessary to optimize
these methods and to combine them in a
logical manner. In doing so, a proactive
approachshouldbeadoptedfromtheﬁrst
dayofdiagnosis,anapproachstigmatized
in the recent American Association of
Clinical Endocrinologists consensus:
“adopt an uncompromising insistence on
treating to target” (25). Adverse events
may be a matter of concern when such
insistence is implemented, but again,
conscious use of agents in combination
can reduce such a risk.
There is no chance of maintaining
good results without a close partnership
betweenthehealthcareprovidersandthe
diabetic patient. Both sides should un-
dergo a continuous, reciprocal educa-
tional program with veriﬁcation and
updating of information, and all efforts
should be made to ensure efﬁcacious
communication. For this purpose, estab-
lishing a diabetes team appears to play an
important role. Financial constraints may
limit the size, but although it may be
small,itiscrucialthatthemedicalperson-
nel aim at well-deﬁned goals and follow
deﬁnite and shared management
protocols.
However, three main “innovations”
are seminal in the change in treatment
paradigm. The ﬁrst is that we now have
the tools to aim treatment at reversal of
themechanismsresponsibleforevolution
of the disease. Recognizing that alter-
ations are already present in individuals
with minor disturbance of glucose toler-
ance and that allowing hyperglycemia to
develop can only worsen those mecha-
nisms sets the rationale for early intensive
combination treatment. Therefore, at the
time of diagnosis, even if glucose param-
eter is only slightly above diagnostic
thresholds, insulin action in peripheral
tissueshouldbeameliorated,suppression
Figure 1—Percentage of type 2 diabetic patients achieving treatment targets for glucose, total
cholesterol, and blood pressure in NHANES 1999–2004 (44).  , 1999; f, 2004.
Type 2 diabetes treatment
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and -cell function supported. Such an
approach is mainly, but not totally, fo-
cused on glycemic control. Thus, amelio-
ration of insulin resistance can be
expected to result in a better proﬁle of CV
risk.
PreventionofCVmorbidityandmor-
tality remains a major task in the manage-
ment of type 2 diabetes. A holistic
approach is then necessary, as suggested
by the results of the Steno-2 studies
(43,44). Intensiﬁed multifactorial inter-
vention,withtightglucoseregulationand
the use of renin-angiotensin system
blockers, aspirin, and lipid-lowering
agents, and behavior modiﬁcation have
sustainedbeneﬁcialeffectswithrespectto
vascularcomplicationsandalowerriskof
death from CV causes (43,44). Although
this approach may be quite effective, it
may not be that simple to implement in
the diabetic community. It has been
proven that control of blood glucose lev-
els, blood pressure, and cholesterol levels
reducestheriskofvasculardiseaseamong
type2diabeticpatients;however,thecur-
rent state of control of these risk factors
among individuals is uncertain. Analysis
of the U.S. National Health and Nutrition
Examination Survey (NHANES) database
indicated that the number of people
achieving target values for all the afore-
mentioned risk factors remains unsatis-
factory and does not change dramatically
over time (45). These data are summa-
rized in Fig. 1. It can be appreciated that
although a positive trend may be appar-
ent, no more than 13.2% of patients in
NHANES 1999–2004 attained recom-
mended goals of A1C level 7%, blood
pressure 130/80 mmHg, and total cho-
lesterol level 200 mg/dl (5.18 mmol/l).
Therefore, while further public health ef-
forts are needed to control CV risk factors
among diabetic individuals, other solu-
tions should be sought.
DiabeteshasbeendeﬁnedasaCVrisk
factor equivalent (46); thus, one potential
solution may simply be prevention of di-
abetes. Several trials have shown that
lifestyle modiﬁcation is effective in pre-
venting incident type 2 diabetes in high-
risk groups (47). Whether diabetes
prevention strategies ultimately will pre-
vent the development of diabetic vascular
complications is unknown, but CV risk
factors are all favorably affected.
Finally, a major cultural and practical
effort must be made to face the increasing
health demand of an ever-increasing
numberoftype2diabeticpatients.Ashift
in the paradigm of treatment is needed
and should aim at deﬁnite objectives, as
already dictated by the diabetes commu-
nity: “Diabetes must be prevented sooner
and diagnosed earlier (48).” “…And once
diagnosed, all types of diabetes must then
be managed much more aggressively”
(49).
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